-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
BMS-707035
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/729607-74-3.gif)
| Category | HIV Integrase |
| CAS | 729607-74-3 |
| Description | BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. |
Product Information
| Synonyms | BMS-707035; BMS-707035; BMS-707035. |
| IUPAC Name | 2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide |
| Molecular Weight | 410.42 |
| Molecular Formula | C17H19FN4O5S |
| Canonical SMILES | CN1C(=O)C(=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(C=C3)F)O |
| InChI | InChI=1S/C17H19FN4O5S/c1-21-16(25)14(23)13(15(24)19-10-11-4-6-12(18)7-5-11)20-17(21)22-8-2-3-9-28(22,26)27/h4-7,23H,2-3,8-10H2,1H3,(H,19,24) |
| InChIKey | VNIWZCGZPBJWBI-UHFFFAOYSA-N |
| Purity | >98% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | DMSO: 38 mg/mL (92.58 mM) Water: Insoluble Ethanol: Insoluble |
| Appearance | Solid powder |
| Application | HIV Integrase Inhibitors |
| Storage | Powder: -20°C 3 years In solvent: -80°C 2 years |
| Complexity | 812 |
| Exact Mass | 410.10601905 |
| Index Of Refraction | 1.670 |
| PSA | 133.47000 |
| Target | HIV |
| XLogP3-AA | 1 |
